Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Gestational Trophoblastic Neoplasia

  • Author: Enrique Hernandez, MD, FACOG, FACS; Chief Editor: Warner K Huh, MD  more...
 
Updated: Mar 05, 2015
 

Practice Essentials

Gestational trophoblastic neoplasia (GTN) is a collective term for gestational trophoblastic diseases that invade locally or metastasize. Hydatidiform mole is the most common form of GTN (see the image below); others are invasive mole (chorioadenoma destruens), choriocarcinoma, and placental site trophoblastic tumor (PSTT).

Histologic section of a complete hydatidiform mole Histologic section of a complete hydatidiform mole stained with hematoxylin and eosin. Villi of different sizes are present. The large villous in the center exhibits marked edema with a fluid-filled central cavity known as cisterna. Marked proliferation of the trophoblasts is observed. The syncytiotrophoblasts stain purple, while the cytotrophoblasts have a clear cytoplasm and bizarre nuclei. No fetal blood vessels are in the mesenchyme of the villi.

Signs and symptoms

Most cases of GTN are diagnosed when the serum hCG levels plateau or rise in patients being observed after the diagnosis of hydatidiform mole. If metastases have developed, the following signs and symptoms may be noted:

  • Metastasis to the lower genital tract presents as purple to blue-black papules or nodules, which are extremely vascular and may bleed profusely if biopsied [1]
  • Abdominal tenderness, if liver or gastrointestinal metastases have occurred
  • Abdominal guarding and rebound tenderness, if a hemoperitoneum has occurred due to bleeding from an abdominal metastasis
  • Bleeding from a metastasis could also result in signs and symptoms of hemorrhagic shock [2, 3]
  • Neurologic deficits, from lethargy to coma, if brain metastasis has occurred
  • Jaundice, if liver metastasis causes biliary obstruction

See Clinical Presentation for more detail.

Diagnosis

Laboratory studies used in the diagnosis of GTN are as follows:

  • Serum quantitative hCG – To assess response to therapy and disease status
  • CBC – May help detect anemia secondary to bleeding
  • Liver enzymes – May become elevated in patients with metastasis to the liver

Imaging studies

  • Pelvic ultrasonography – May show persistent molar tissue in the uterus
  • Chest radiograph – Recommended because the lung is the most frequent site of metastasis
  • CT scan of the chest (optional)
  • CT scan of the abdomen and pelvis with contrast
  • MRI of the head (preferable to CT)

CT and MRI are recommended if the patient has hydatidiform mole with metastasis to the lungs, choriocarcinoma, or persistent hydatidiform mole. The lungs, lower genital tract, brain, liver, kidney, and gastrointestinal tract are common sites of metastases.

Procedures

  • Suction and careful sharp curettage could be performed in patients being observed for a hydatidiform mole who have persistent vaginal bleeding and tissue within the endometrial cavity on pelvic ultrasonography
  • Uterine dilatation and curettage (D&C) performed in a woman with abnormal vaginal bleeding and a positive pregnancy test result may reveal a choriocarcinoma

Features of a D&C are as follows:

  • A D&C may be part of the evaluation of a patient with an elevated serum hCG level of unknown origin
  • The tissue is sent for histopathologic examination
  • Examination may reveal a hydatidiform mole (complete or partial) or a choriocarcinoma
  • Rarely is a histopathologic diagnosis of an invasive mole made on a D&C specimen, because this requires the identification of destructive invasion of the myometrium by the trophoblasts
  • Typically, scant or no myometrium is recovered on a D&C specimen
  • Rarely is the diagnosis of PSTT made on a D&C specimen, since this usually presents as intermediate trophoblasts infiltrating the myometrium

Staging and prognostic scoring

The official International Federation of Gynecology and Obstetrics staging of gestational trophoblastic neoplasia is as follows[4, 5] :

  • Stage I – Confined to the uterus
  • Stage II – Limited to the genital structures
  • Stage III – Lung metastases
  • Stage IV – Other metastases

The currently used prognostic scoring index is a modification of the World Health Organization (WHO) classification. Scores are determined by adding up points from a list of 19 prognostic factors.

See Workup for more detail.

Management

Patients with nonmetastatic GTN or metastatic low-risk GTN are treated with single-agent chemotherapy, as follows[6, 7, 8, 9, 10, 11] :

  • Methotrexate is preferred by many US specialists, but actinomycin D can be used in patients with poor liver function
  • During treatment, the serum hCG levels are monitored every week
  • Six weeks of maintenance chemotherapy is administered after a normal serum hCG level
  • After 3-4 normal serum hCG levels, the levels are observed once per month for 1 year
  • A switch from methotrexate to actinomycin D is made if the serum hCG levels rise or plateau

Patients with high-risk metastatic GTN are subdivided into 2 groups: those with a WHO score of less than 7 and those with a score of 7 or higher and who are at high risk of therapy failure. Patients with a WHO score of less than 7 can be treated with single-agent chemotherapy (methotrexate or actinomycin D).[12] Six weeks of maintenance chemotherapy is administered after a normal serum hCG level is achieved.

Treatment in patients with WHO scores of 7 or higher is as follows:

  • EMA-CO regimen – A combination of etoposide, methotrexate, and actinomycin D administered in the first week of a 2-week cycle, and cyclophosphamide and vincristine (Oncovin) administered in the second week [13, 14, 15, 16]
  • EMA-CE regimen – Cisplatin and etoposide are substituted for cyclophosphamide and vincristine during the second week [17] ; sometimes reserved for patients in whom EMA-CO fails
  • At least 6 weeks of maintenance EMA-CO or EMA-CE are administered after a normal serum hCG level
  • Patients with liver metastasis are considered for liver irradiation (2000 cGy) [18]

Brain metastasis treatment

  • Whole brain irradiation (3000 cGy) is given in combination with chemotherapy [19, 20, 21] ; dexamethasone is administered to reduce brain edema (most common approach in US)
  • Early neurosurgical intervention for solitary lesions or stereotactic radiotherapy for multiple lesions or solitary lesions in locations at high risk for surgical morbidity, [22] followed by moderate- and high-dose intravenous methotrexate and, at some centers, intrathecal methotrexate (approach used in selected institutions)
  • A therapeutic level of methotrexate is achieved in the cerebrospinal fluid at IV doses of >600 mg/m 2[22]
  • In patients not receiving whole brain irradiation, the dose of methotrexate on day 1 of the EMA-CO or EMA-CE regimen is increased to 1000 mg/m 2
  • Instead of 4 doses of folinic acid (15 mg every 12 hours), 12 doses (15 mg every 6 hours) are given, starting 24 hours after the initiation of methotrexate infusion

Stage IV GTN

  • Patients with stage IV GTN are most often treated with multiagent chemotherapy, even when the WHO score is less than 7, which is uncommon
  • After achieving 3-4 consecutive weekly normal serum hCG levels, patients with stage IV GTN are observed with monthly serum hCG levels for 2 years
  • If the levels begin to rise during follow-up, the patient is evaluated for possible intervening pregnancy, or persistent or recurrent disease

Surgical care

  • Uterine or hypogastric artery ligation or embolization of feeding vessels may be needed to control hemorrhage; hepatic artery embolization has been used successfully to control hemorrhage from hepatic metastases [2]
  • A hysterectomy may be necessary in case of uncontrolled vaginal bleeding
  • Craniotomy may be needed to control bleeding and provide decompression [15, 22]
  • Resection of solitary metastasis (eg, thoracotomy) or disease within the myometrium may help achieve a remission [23, 24, 25]
  • Hysterectomy, [26, 27] or a repeat D&C in patients with persistent tissue on pelvic ultrasonography, may reduce the number of chemotherapy cycles needed to achieve remission [28]
  • A hysterectomy is the treatment of choice for PSTT; the ovaries do not need to be removed if the patient is premenopausal [29]

See Treatment and Medication for more detail.

Next

Background

Gestational trophoblastic disease (GTD) can be benign or malignant. Histologically, it is classified into hydatidiform mole, invasive mole (chorioadenoma destruens), choriocarcinoma, and placental site trophoblastic tumor (PSTT). Those that invade locally or metastasize are collectively known as gestational trophoblastic neoplasia (GTN). Hydatidiform mole is the most common form of GTN. While invasive mole and choriocarcinoma are malignant, a hydatidiform mole can behave in a malignant or benign fashion.

Histologic section of a complete hydatidiform mole Histologic section of a complete hydatidiform mole stained with hematoxylin and eosin. Villi of different sizes are present. The large villous in the center exhibits marked edema with a fluid-filled central cavity known as cisterna. Marked proliferation of the trophoblasts is observed. The syncytiotrophoblasts stain purple, while the cytotrophoblasts have a clear cytoplasm and bizarre nuclei. No fetal blood vessels are in the mesenchyme of the villi.

No methods exist to accurately predict the clinical behavior of a hydatidiform mole by histopathology. The clinical course is defined by the patient's serum human chorionic gonadotropin (hCG) curve after evacuation of the mole. In 80% of patients with a benign hydatidiform mole, serum hCG levels steadily drop to normal within 8-12 weeks after evacuation of the molar pregnancy. In the other 20% of patients with a malignant hydatidiform mole, serum hCG levels either rise or plateau.[4, 30]

The International Federation of Gynecology and Obstetrics considers an elevated serum hCG level 6 or more months after evacuation of a hydatidiform mole to be diagnostic of malignancy (ie, GTN). However, serum hCG levels spontaneously return to normal without chemotherapy in most patients with elevated but still declining serum hCG levels 6 months after diagnosis of a hydatidiform mole. Therefore, continuing to follow these patients is reasonable as long as the hCG levels do not rise or plateau.[31]

For more information on hydatidiform mole, see the Medscape Reference article Hydatidiform Mole.

Previous
Next

Pathophysiology

A hydatidiform mole is considered malignant when the serum hCG levels plateau or rise during the follow-up period and an intervening pregnancy is excluded. This occurs in 15-20% of hydatidiform moles.[4, 30, 32]

A hydatidiform mole with a fetus or fetal tissue and a triploid karyotype is known as a partial or incomplete mole. Partial moles also have malignant potential, but only 2-3% become malignant.[33, 34, 35] Cases of partial hydatidiform moles with lung metastasis have been reported and at least one case of choriocarcinoma on a biopsy from a vaginal metastasis has been reported in a patient being observed for a partial hydatidiform mole.[36, 37]

An invasive mole has the same histopathologic characteristics of a hydatidiform mole, but invasion of the myometrium with necrosis and hemorrhage occurs or pulmonary metastases are present.

Histologically, choriocarcinomas have no villi, but they have sheets of trophoblasts and hemorrhage. Choriocarcinomas are aneuploid and can be heterozygous depending on the type of pregnancy from which the choriocarcinoma arose. If a hydatidiform mole preceded the choriocarcinoma, the chromosomes are of paternal origin. Maternal and paternal chromosomes are present if a term pregnancy precedes the choriocarcinoma. Of choriocarcinomas, 50% are preceded by a hydatidiform mole, 25% by an abortion, 3% by ectopic pregnancy, and the other 22% by a full-term pregnancy.[4] Choriocarcinoma has also been associated with ectopic pregnancy with a theoretic incidence of 1 in 5333 ectopic pregnancies.[38]

Placental site trophoblastic tumor is a rare form of gestational trophoblastic neoplasia, with slightly more than 200 cases reported in the literature.[39, 40] In patients with PSTT, intermediate trophoblasts are found infiltrating the myometrium without causing tissue destruction. The intermediate trophoblasts contain human placental lactogen (hPL).[41] These patients have persistent low levels of serum hCG (100-1000 mIU/mL). However, serum hCG levels as high as 108,000 mIU/mL have been reported in patients with PSTT.[42] The treatment of PSTT is hysterectomy with ovarian conservation.[29] If the tumor recurs or metastases are present at initial diagnosis, chemotherapy is administered with variable results.[43, 44] Radiation therapy may provide local control.

The most frequent sites of metastases of malignant gestational trophoblastic neoplasia are the lungs, lower genital tract, brain, liver, kidney, and gastrointestinal tract.

In this microphotograph of a choriocarcinoma metas In this microphotograph of a choriocarcinoma metastatic to the brain, the neuropil is seen on the right and the biphasic (2 cell populations) choriocarcinoma is seen to the left with hemorrhage at the left border of the photograph (H&E stain).
Previous
Next

Frequency

United States

Gestational trophoblastic neoplasia is diagnosed in 15-20% of patients with a complete hydatidiform mole and 2% of partial hydatidiform moles. Lung metastases are found in 4-5% of patients with complete hydatidiform moles and rarely in cases of partial hydatidiform moles.

Choriocarcinoma occurs in 1 out of 40 hydatidiform moles and in 1 out of 20,000-40,000 pregnancies.[4, 45] However, only 1 out of 160,000 term pregnancies is followed by a choriocarcinoma.[46]

International

The international rate of choriocarcinoma has been reported to be as high as 1 in 500-600 pregnancies in India to 1 in 50,000 pregnancies in Mexico, Paraguay, and Sweden.[45, 47, 48] These differences are probably due to differences in methodology (eg, identification of cases, accuracy of denominator).[45, 47]

Race-, sex-, age-related demographics

Little information is available on international ethnic or racial differences of the incidence of choriocarcinoma. In the United States, African Americans have the highest incidence of choriocarcinoma and the lowest survival rates.[49]

Gestational trophoblastic neoplasia affects women during their reproductive years. However, placental site trophoblastic tumors have been diagnosed when patients were postmenopausal.

The incidence of choriocarcinoma increases with age and is 5-15 times higher in women 40 years and older than in younger women.[47]

Previous
Next

Prognosis

Nonmetastatic GTN has a cure rate of close to 100% with chemotherapy treatment.

Metastatic low-risk GTN has a cure rate of close to 100% with chemotherapy treatment. Metastatic high-risk GTN has a cure rate of approximately 75% with chemotherapy treatment.

After 12 months of normal hCG levels, less than 1% of patients with GTN have recurrences.

Morbidity/mortality

Patients who have a malignant hydatidiform mole, an invasive mole, or a choriocarcinoma should undergo a systematic search for metastases. Patients who have metastases are classified as high-risk or low-risk according to the National Institutes of Health classification.[30] The criteria for high-risk metastatic gestational trophoblastic neoplasia include hepatic or brain metastasis, serum hCG levels greater than 40,000 mIU/mL prior to the initiation of chemotherapy, duration of disease longer than 4 months, prior unsuccessful chemotherapy, and malignant gestational trophoblastic neoplasia following a term pregnancy.

As noted above, patients with malignant nonmetastatic or metastatic low-risk gestational trophoblastic neoplasia have an almost 100% probability of cure with chemotherapy. The probability of cure after chemotherapy for patients with metastatic high-risk gestational trophoblastic neoplasia is approximately 75%.[50]

The probability of a late recurrence after the patient has been in remission (normal serum beta-hCG titers) for 1 year is less than 1%.[30, 51]

See Prognosis section for more information on recurrence rate.

Complications

Plateauing or rising serum hCG levels during the period of follow-up care may indicate a normal intrauterine pregnancy or GTN with or without metastasis.

Etoposide is associated with an increased risk of developing leukemia. It should be used only in patients with high-risk disease.[52]

The rate of abnormal pregnancies (spontaneous abortions, stillbirths, repeat GTD) is higher if a subsequent pregnancy occurs within 6 months of completing chemotherapy, compared with pregnancies that occur after 12 months.[53]

Previous
 
 
Contributor Information and Disclosures
Author

Enrique Hernandez, MD, FACOG, FACS Chairman, Department of Obstetrics and Gynecology, Director of Gynecologic Oncology, Abraham Roth Professor of Obstetrics, Gynecology and Reproductive Science, Professor of Pathology, Temple University Hospital, Temple University School of Medicine

Enrique Hernandez, MD, FACOG, FACS is a member of the following medical societies: Alpha Omega Alpha, American Cancer Society, Association of Professors of Gynecology and Obstetrics, Pennsylvania Medical Society, Philadelphia County Medical Society, Society of Gynecologic Oncology, American Society for Colposcopy and Cervical Pathology, Johns Hopkins Medical and Surgical Association, American Gynecological and Obstetrical Society, American College of Obstetricians and Gynecologists, American College of Surgeons, American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Jori S Carter, MD, MS Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Virginia Commonwealth University School of Medicine

Jori S Carter, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology, Association of Women Surgeons, International Society for Magnetic Resonance in Medicine, American Society of Clinical Oncology

Disclosure: Nothing to disclose.

Chief Editor

Warner K Huh, MD Professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Senior Scientist, Comprehensive Cancer Center, University of Alabama School of Medicine

Warner K Huh, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American College of Surgeons, Massachusetts Medical Society, Society of Gynecologic Oncology, American Society of Clinical Oncology

Disclosure: I have received consulting fees for: Merck; THEVAX.

Additional Contributors

Robert C Shepard, MD, FACP Associate Professor of Medicine in Hematology and Oncology at University of North Carolina at Chapel Hill; Vice President of Scientific Affairs, Therapeutic Expertise, Oncology, at PRA International

Robert C Shepard, MD, FACP is a member of the following medical societies: American Association for Cancer Research, American Association for Physician Leadership, European Society for Medical Oncology, Association of Clinical Research Professionals, American Federation for Clinical Research, Eastern Cooperative Oncology Group, Society for Immunotherapy of Cancer, American Medical Informatics Association, American College of Physicians, American Federation for Medical Research, American Medical Association, American Society of Hematology, Massachusetts Medical Society

Disclosure: Nothing to disclose.

References
  1. Yingna S, Yang X, Xiuyu Y, et al. Clinical characteristics and treatment of gestational trophoblastic tumor with vaginal metastasis. Gynecol Oncol. 2002 Mar. 84(3):416-9. [Medline].

  2. Grumbine FC, Rosenshein NB, Brereton HD, et al. Management of liver metastasis from gestational trophoblastic neoplasia. Am J Obstet Gynecol. 1980 Aug 15. 137(8):959-61. [Medline].

  3. Soper JT, Mutch DG, Chin N, et al. Renal metastases of gestational trophoblastic disease: a report of eight cases. Obstet Gynecol. 1988 Nov. 72(5):796-8. [Medline].

  4. Smith HO, Kohorn E, Cole LA. Choriocarcinoma and gestational trophoblastic disease. Obstet Gynecol Clin North Am. 2005 Dec. 32(4):661-84. [Medline].

  5. Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med. 2002 Jun. 47(6):445-50. [Medline].

  6. Soper JT, Clarke-Pearson DL, Berchuck A, et al. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol. 1994 Jul. 54(1):76-9. [Medline].

  7. Foulmann K, Guastalla JP, Caminet N, et al. What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecol Oncol. 2006 Jul. 102(1):103-10. [Medline].

  8. Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol. 1996 Jun. 174(6):1917-23; discussion 1923-4. [Medline].

  9. Matsui H, Suzuka K, Yamazawa K, et al. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy. Gynecol Oncol. 2005 Mar. 96(3):616-20. [Medline].

  10. Kohorn EI. Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance?. Gynecol Oncol. 2002 Apr. 85(1):36-9. [Medline].

  11. Homesley HD, Blessing JA, Schlaerth J, et al. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Dec. 39(3):305-8. [Medline].

  12. Ngan HY, Odicino F, Maisonneuve P, Creasman WT, Beller U, Quinn MA, et al. Gestational trophoblastic neoplasia. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov. 95 Suppl 1:S193-203. [Medline].

  13. Lurain JR. Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med. 2002 Jun. 47(6):451-9. [Medline].

  14. Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med. 2006 Oct. 51(10):767-72. [Medline].

  15. Lehman E, Gershenson DM, Burke TW, et al. Salvage surgery for chemorefractory gestational trophoblastic disease. J Clin Oncol. 1994 Dec. 12(12):2737-42. [Medline].

  16. Escobar PF, Lurain JR, Singh DK, et al. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol. 2003 Dec. 91(3):552-7. [Medline].

  17. Xiang Y, Sun Z, Wan X, et al. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor. J Reprod Med. 2004 Jun. 49(6):443-6. [Medline].

  18. Barnard DE, Woodward KT, Yancy SG, et al. Hepatic metastases of choriocarcinoma: a report of 15 patients. Gynecol Oncol. 1986 Sep. 25(1):73-83. [Medline].

  19. Yordan EL Jr, Schlaerth J, Gaddis O, et al. Radiation therapy in the management of gestational choriocarcinoma metastatic to the central nervous system. Obstet Gynecol. 1987 Apr. 69(4):627-30. [Medline].

  20. Cagayan MS, Lu-Lasala LR. Management of gestational trophoblastic neoplasia with metastasis to the central nervous system: A 12-year review at the Philippine General Hospital. J Reprod Med. 2006 Oct. 51(10):785-92. [Medline].

  21. Schechter NR, Mychalczak B, Jones W, et al. Prognosis of patients treated with whole-brain radiation therapy for metastatic gestational trophoblastic disease. Gynecol Oncol. 1998 Feb. 68(2):183-92. [Medline].

  22. Soper JT, Spillman M, Sampson JH, et al. High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. Gynecol Oncol. 2007 Mar. 104(3):691-4. [Medline].

  23. Rojas-Espaillat L, Houck KL, Hernandez E, et al. Fertility-sparing surgery for persistent gestational trophoblastic neoplasia in the myometrium: a case report. J Reprod Med. 2007 May. 52(5):431-4. [Medline].

  24. Jones WB, Romain K, Erlandson RA, et al. Thoracotomy in the management of gestational choriocarcinoma. A clinicopathologic study. Cancer. 1993 Oct 1. 72(7):2175-81. [Medline].

  25. Carlson N, Winter WE 3rd, Krivak TC, et al. Successful management of metastatic placental site trophoblastic tumor with multiple pulmonary resections. Gynecol Oncol. 2002 Oct. 87(1):146-9. [Medline].

  26. Hammond CB, Weed JC Jr, Currie JL. The role of operation in the current therapy of gestational trophoblastic disease. Am J Obstet Gynecol. 1980 Apr 1. 136(7):844-58. [Medline].

  27. Suzuka K, Matsui H, Iitsuka Y, et al. Adjuvant hysterectomy in low-risk gestational trophoblastic disease. Obstet Gynecol. 2001 Mar. 97(3):431-4. [Medline].

  28. van Trommel NE, Massuger LF, Verheijen RH, et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol. 2005 Oct. 99(1):6-13. [Medline].

  29. Berkowitz BJ, Jones JG, Merkatz IR, et al. Ovarian conservation in placental site trophoblastic tumor. Gynecol Oncol. 1990 May. 37(2):239-43. [Medline].

  30. Soper JT. Gestational trophoblastic disease. Obstet Gynecol. 2006 Jul. 108(1):176-87. [Medline].

  31. Agarwal R, Teoh S, Short D, et al. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet. 2012 Jan 14. 379(9811):130-5. [Medline].

  32. Yuen BH, Cannon W. Molar pregnancy in British Columbia: estimated incidence and postevacuation regression patterns of the beta subunit of human chorionic gonadotropin. Am J Obstet Gynecol. 1981 Feb 1. 139(3):316-9. [Medline].

  33. Goto S, Yamada A, Ishizuka T, et al. Development of postmolar trophoblastic disease after partial molar pregnancy. Gynecol Oncol. 1993 Feb. 48(2):165-70. [Medline].

  34. Hancock BW, Tidy JA. Current management of molar pregnancy. J Reprod Med. 2002 May. 47(5):347-54. [Medline].

  35. Watson EJ, Hernandez E, Miyazawa K. Partial hydatidiform moles: a review. Obstet Gynecol Surv. 1987 Sep. 42(9):540-4. [Medline].

  36. Cheung AN, Khoo US, Lai CY, et al. Metastatic trophoblastic disease after an initial diagnosis of partial hydatidiform mole: genotyping and chromosome in situ hybridization analysis. Cancer. 2004 Apr 1. 100(7):1411-7. [Medline].

  37. Menczer J, Girtler O, Zajdel L, et al. Metastatic trophoblastic disease following partial hydatidiform mole: case report and literature review. Gynecol Oncol. 1999 Aug. 74(2):304-7. [Medline].

  38. Lurain JR, Sand PK, Brewer JI. Choriocarcinoma associated with ectopic pregnancy. Obstet Gynecol. 1986 Aug. 68(2):286-7. [Medline].

  39. Baergen RN, Rutgers JL, Young RH, et al. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol. 2006 Mar. 100(3):511-20. [Medline].

  40. Tsuji Y, Tsubamoto H, Hori M, et al. Case of PSTT treated with chemotherapy followed by open uterine tumor resection to preserve fertility. Gynecol Oncol. 2002 Dec. 87(3):303-7. [Medline].

  41. Nigam S, Singhal N, Kumar Gupta S, et al. Placental site trophoblastic tumor in a postmenopausal female--a case report. Gynecol Oncol. 2004 May. 93(2):550-3. [Medline].

  42. Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol. 2005 Dec. 99(3):603-7. [Medline].

  43. Zhao J, Xiang Y, Wan XR, et al. Clinical and pathologic characteristics and prognosis of placental site trophoblastic tumor. J Reprod Med. 2006 Dec. 51(12):939-44. [Medline].

  44. Papadopoulos AJ, Foskett M, Seckl MJ, et al. Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med. 2002 Jun. 47(6):460-4. [Medline].

  45. Grimes DA. Epidemiology of gestational trophoblastic disease. Am J Obstet Gynecol. 1984 Oct 1. 150(3):309-18. [Medline].

  46. McDonald TW, Ruffolo EH. Modern management of gestational trophoblastic disease. Obstet Gynecol Surv. 1983 Feb. 38(2):67-83. [Medline].

  47. Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med. 1994 Mar. 39(3):155-62. [Medline].

  48. Chakrabarti BK, Mondal NR, Chatterjee T. Gestational trophoblastic tumor at a tertiary level cancer center: a retrospective study. J Reprod Med. 2006 Nov. 51(11):875-8. [Medline].

  49. Smith HO, Qualls CR, Prairie BA, et al. Trends in gestational choriocarcinoma: a 27-year perspective. Obstet Gynecol. 2003 Nov. 102(5 Pt 1):978-87. [Medline].

  50. Soper JT, Evans AC, Conaway MR, et al. Evaluation of prognostic factors and staging in gestational trophoblastic tumor. Obstet Gynecol. 1994 Dec. 84(6):969-73. [Medline].

  51. Mutch DG, Soper JT, Babcock CJ, et al. Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer. 1990 Sep 1. 66(5):978-82. [Medline].

  52. Rustin GJ, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996 Oct. 14(10):2769-73. [Medline].

  53. Matsui H, Iitsuka Y, Suzuka K, et al. Risk of abnormal pregnancy completing chemotherapy for gestational trophoblastic tumor. Gynecol Oncol. 2003 Feb. 88(2):104-7. [Medline].

  54. Fulop V, Mok SC, Berkowitz RS. Molecular biology of gestational trophoblastic neoplasia: a review. J Reprod Med. 2004 Jun. 49(6):415-22. [Medline].

  55. Fong PY, Xue WC, Ngan HY, et al. Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: a differential expression study. Cancer. 2005 Jan 15. 103(2):268-76. [Medline].

  56. Kim SJ, Park SE, Lee C, et al. Altered imprinting, promoter usage, and expression of insulin-like growth factor-II gene in gestational trophoblastic diseases. Gynecol Oncol. 2003 Mar. 88(3):411-8. [Medline].

  57. Olsen TG, Barnes AA, King JA. Elevated HCG outside of pregnancy--diagnostic considerations and laboratory evaluation. Obstet Gynecol Surv. 2007 Oct. 62(10):669-74; quiz 691. [Medline].

  58. Olsen TG, Hubert PR, Nycum LR. Falsely elevated human chorionic gonadotropin leading to unnecessary therapy. Obstet Gynecol. 2001 Nov. 98(5 Pt 1):843-5. [Medline].

  59. Khanlian SA, Cole LA. Management of gestational trophoblastic disease and other cases with low serum levels of human chorionic gonadotropin. J Reprod Med. 2006 Oct. 51(10):812-8. [Medline].

  60. Matsui H, Iitsuka Y, Suzuka K, et al. Salvage chemotherapy for high-risk gestational trophoblastic tumor. J Reprod Med. 2004 Jun. 49(6):438-42. [Medline].

  61. Knox S, Brooks SE, Wong-You-Cheong J, et al. Choriocarcinoma and epithelial trophoblastic tumor: successful treatment of relapse with hysterectomy and high-dose chemotherapy with peripheral stem cell support: a case report. Gynecol Oncol. 2002 Apr. 85(1):204-8. [Medline].

  62. Ngan HY, Chan FL, Au VW, et al. Clinical outcome of micrometastasis in the lung in stage IA persistent gestational trophoblastic disease. Gynecol Oncol. 1998 Aug. 70(2):192-4. [Medline].

  63. Gamer EI, Garrett A, Goldstein DP, et al. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med. 2004 Jun. 49(6):411-4. [Medline].

  64. Fukunaga M. Immunohistochemical characterization of p57(KIP2) expression in early hydatidiform moles. Hum Pathol. 2002 Dec. 33(12):1188-92. [Medline].

  65. FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet. 2002 Jun. 77(3):285-7. [Medline].

  66. Boggs W. New Guideline for Gestational Trophoblastic Disease. Available at http://www.medscape.com/viewarticle/811689. Accessed: September 30, 2013.

  67. Seckl MJ, Sebire NJ, Fisher RA, et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Sep 1. [Medline].

  68. Kashimura Y, Kashimura M, Sugimori H, et al. Prophylactic chemotherapy for hydatidiform mole. Five to 15 years follow-up. Cancer. 1986 Aug 1. 58(3):624-9. [Medline].

  69. Massad LS, Abu-Rustum NR, Lee SS, et al. Poor compliance with postmolar surveillance and treatment protocols by indigent women. Obstet Gynecol. 2000 Dec. 96(6):940-4. [Medline].

  70. Osborne R, Filiaci V, Schink J, et al. A randomized phase III trial comparing weekly parenteral methotrexate and "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecol Oncol. 2008. 108:S2-S3.

  71. Woolas RP, Bower M, Newlands ES, et al. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynaecol. 1998 Sep. 105(9):1032-5. [Medline].

  72. Lok CA, van der Houwen C, ten Kate-Booij MJ, et al. Pregnancy after EMA/CO for gestational trophoblastic disease: a report from The Netherlands. BJOG. 2003 Jun. 110(6):560-6. [Medline].

 
Previous
Next
 
Histologic section of a complete hydatidiform mole stained with hematoxylin and eosin. Villi of different sizes are present. The large villous in the center exhibits marked edema with a fluid-filled central cavity known as cisterna. Marked proliferation of the trophoblasts is observed. The syncytiotrophoblasts stain purple, while the cytotrophoblasts have a clear cytoplasm and bizarre nuclei. No fetal blood vessels are in the mesenchyme of the villi.
In this microphotograph of a choriocarcinoma metastatic to the brain, the neuropil is seen on the right and the biphasic (2 cell populations) choriocarcinoma is seen to the left with hemorrhage at the left border of the photograph (H&E stain).
Table. Prognostic Scoring Index
Prognostic Factor Points
Age ≥40 y 1
Antecedent pregnancy terminated in abortion 1
Antecedent full-term pregnancy 2
Interval of 4-7 mo between antecedent pregnancy and start of chemotherapy 1
Interval of 7-12 mo between antecedent pregnancy and start of chemotherapy 2
Interval of more than 12 mo between antecedent pregnancy and start of chemotherapy 4
Beta-hCG level in serum is 1,000 to < 10,000 mIU/mL 1
Beta-hCG level in serum is 10,000 to < 100,000 mIU/mL 2
Beta-hCG level in serum is ³100,000 mIU/mL 4
Largest tumor is 3 cm to < 5 cm 1
Largest tumor is ³5 cm 2
Site of metastases is spleen or kidney 1
Site of metastases is gastrointestinal tract 2
Site of metastases is brain or liver 4
Number of metastases is 1-4 1
Number of metastases is 5-8 2
Number of metastases is >8 4
Prior chemotherapy with single drug 2
Prior chemotherapy with multiple drugs 4
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.